Sk Life Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SK LIFE, and when can generic versions of SK LIFE drugs launch?
SK LIFE has one approved drug.
There are two US patents protecting SK LIFE drugs.
There are twenty-three patent family members on SK LIFE drugs in twenty countries and eleven supplementary protection certificates in ten countries.
Summary for Sk Life
| International Patents: | 23 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Sk Life
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-003 | Mar 10, 2020 | RX | Yes | No | 7,598,279 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-002 | Mar 10, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-002 | Mar 10, 2020 | RX | Yes | No | 11,654,133 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Sk Life | XCOPRI | cenobamate | TABLET;ORAL | 212839-005 | Mar 10, 2020 | RX | Yes | No | 7,598,279 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Sk Life Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20080005437 | ⤷ Try a Trial |
| South Korea | 101286499 | ⤷ Try a Trial |
| Argentina | 053065 | ⤷ Try a Trial |
| Mexico | 2007013197 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sk Life Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1879873 | 2190019-6 | Sweden | ⤷ Try a Trial | PRODUCT NAME: CENOBAMATE OR A PHARMACEUTICAL ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1530 20210330 |
| 1879873 | C202130027 | Spain | ⤷ Try a Trial | PRODUCT NAME: CENOBAMATO; NATIONAL AUTHORISATION NUMBER: EU/1/21/1530; DATE OF AUTHORISATION: 20210326; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1530; DATE OF FIRST AUTHORISATION IN EEA: 20210326 |
| 1879873 | 2021C/524 | Belgium | ⤷ Try a Trial | PRODUCT NAME: CENOBAMAAT; AUTHORISATION NUMBER AND DATE: EU/1/21/1530 20210330 |
| 1879873 | C01879873/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: CENOBAMAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68051 19.05.2022 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
